U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07121829) titled 'Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors' on July 03.
Brief Summary: This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants >=12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of the MAPK pathway, such as tumors that harbor RAS or RAF alterations.
*Note: Study concluded as Phase 1b only.
Study Start Date: May 02, 2022
Study Type: INTERVENTIONAL
Condition:
Melanoma
Solid Tumor
Pilocytic Astrocytoma
Non Small Cell Lung Cancer
Colorectal Cancer
Pan...